Sintilimab Combined With Anlotinib as Second- or Further-line Therapy for Extensive Disease Small Cell Lung Cancer: A Prospective, Single-arm, Phase II Study
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Catequentinib (Primary) ; Sintilimab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms Performance
Most Recent Events
- 26 Jun 2023 Interventional study model has changed to Single Group Assignment from Parallel, Time frame of primary endpoint has changed to 8 months.
- 07 Jun 2022 Status changed from recruiting to completed, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.